Междисциплинарный подход к ведению пациенток при прогрессировании рака тела матки
Аннотация
Рак эндометрия является наиболее частым онкогинекологическим заболеванием в России. Хирургия и/или сочетание хирургического лечения, лучевой терапии и химиотерапии остаются стандартом его терапии. данный обзор описывает использование мультидисциплинарного подхода как современного способа ведения пациенток, страдающих раком эндометрия. При этом описаны важность молекулярной оценки в принятии решения и использование новых подходов, таких как иммунотерапия и комбинация ингибиторов контрольных точек и ингибиторов тирозинкиназ.
Об авторах
К. Ю. Морхов
Институт онкогинекологии и маммологии ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» Минздрава России
Россия
Россия
Онкологическое отделение хирургических методов лечения
117198 Москва, ул. Академика Опарина, 4
Ю. М. Крейнина
ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)»
Россия
Россия
Лаборатория лучевой терапии и комплексных методов лечения онкологических заболеваний научно-исследовательского отдела инновационных технологий комплексной диагностики заболеваний и радиотерапии; кафедра онкологии, радиотерапии и пластической хирургии
117485 Москва, ул. Профсоюзная, 86;
119435 Москва, ул. Большая Пироговская, 2, стр. 4
И. А. Покатаев
ГБУЗ «Городская клиническая онкологическая больница № 1 Департамента здравоохранения г. Москвы»
Россия
Россия
Служба химиотерапевтического лечения
117152 Москва, Загородное шоссе, 18А
В. М. Нечушкина
ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России
Россия
Россия
Кафедра онкологии, лучевой терапии и лучевой диагностики
603155 Нижний Новгород, Верхневолжская набережная, 18/1
Список литературы
1. Lortet-Tieulent J., Ferlay J., Bray F. et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018;110(4):354–361. DOI: 10.1093/jnci/djx214.
2. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.
3. Creutzberg C.L., Van Putten W.L., Koper P.C. et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol2003;89(2):201–9.
4. Creutzberg C.L., Nout R.A., Lybeert M.L. et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81(4):e631–8. DOI: 10.1016/j.ijrobp.2011.04.013.
5. Yechieli R., Robbins J.R., Schultz D. et al. Vaginal recurrence more than 17 years after hysterectomy and adjuvant treatment for uterine carcinoma with successful salvage brachytherapy: A case report. Case Rep Oncol 2011;4(1):242–5. DOI:10.1159/000328076.
6. Wylie J., Irwin C., Pintilie M. et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 2000;77(1):66–72. DOI: 10.1006/gyno.2000.5727.
7. Robbins J.R., Yechieli R., Laser B. et al. Is time to recurrence after hysterectomy predictive of survival in patients with early stage endometrial carcinoma? Gynecol Oncol 2012;127(1):38–42.
8. Boruta D.M., Gehrig P.A., Fader A.N., Olawaiye A.B. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115(1):142–53.
9. Olawaiye A.B., Boruta D.M. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;113(2):277–83.
10. Del Carmen M.G., Boruta D.M., Schorge J.O. Recurrent endometrial cancer. Clin Obstet Gynecol 2011;54(2):266–77.
11. Ozen A., Falchook A.D., Varia M.A. et al. Effect of race and histology on patterns of failure in women with early stage endometrial cancer treated with high dose rate brachytherapy. Gynecol Oncol 2015;138(2):429–33.
12. Нечушкина В.М., Морхов К.Ю., Кузнецов В.В. Комбинированное лечение рака тела матки ранних стадий. Сибирский онкологический журнал 2013;(3):70–4.
13. Mariani A., Dowdy S.C., Keeney G.L. et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004;95(1):120–6. DOI: 10.1016/j.ygyno.2004.06.042.
14. Abusaris H., Hoogeman M., Nuyttens J.J. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer ResTreat 2012;11(6):591–7.
15. Alders J.G., Abeler V., Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17(1):85.
16. Нечушкина В.М. Рак тела матки (факторы прогноза и тактика лечения). Дис. ... д-ра мед. наук. М., 2013. 445 с.
17. Xu Y., Burmeister C., Hanna R.K. et al. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer 2016;26 (6):1137–42. DOI:10.1097/IGC.0000000000000733.
18. Schmidt A.M., Imesch P., Fink D. et al. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer 2016;26(4):716–21.
19. Lee L.J., Damato A.L., Viswanathan A.N. Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance. Brachytherapy 2013;12(4):303–10.
20. Hasbini A., Haie-Meder C., Morice P.et al. Outcome after salvage radiotherapy (brachytherapy ± external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol 2002;65(1):23–8. DOI: 10.1016/s0167-8140(02)00212-8.
21. Yard B.D., Adams D.J., Chie E.K. et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun 2016;7:11428.
22. Рак тела матки и саркомы матки. Клинические рекомендации Минздрава России 2021. Доступно по: https://oncology-association.ru/wp-content/uploads/2021/02/rak-tela-matki-isarkomy-matki-2021.pdf.
23. Lindemann K., Smogeli Е., Cvancarova Småstuen M. et al. Salvage radiation for pelvic relapse after surgically treated endometrial cancer. Cancers (Basel) 2021;13(6):1367. DOI: 10.3390/cancers13061367.
24. Steiner A., Alban G., Cheng T. Vaginal recurrence of endometrial cancer: MRI characteristics and correlation with patient outcome after salvage radiation therapy. Abdom Radiol (NY) 2020;45(4):1122–31.
25. Титова В.А., Столярова И.В., Крейнина Ю.М. Современные технологии комплексного лечения рака эндометрия: научно-практическое издание. Москва, Санкт-Петербург: Фолиант, 2012. 168 с.
26. Mehta S., Gupta B. Recent advances in endometrial cancer. Springer, 2020. Pp. 257–266.
27. Jhingran A., Burke T.W., Eifel P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys2003;56:1366–72.
28. Blecharz P., Brandys P., Urbański K. et al. Vaginal and pelvic recurrences in stage I and II endometrial carcinoma survival and prognostic factors. Eur J Gynaecol Oncol 2011;32:403–7.
29. Nag S., Yacoub S., Copeland L.J., Fowler J.M. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. Int J Radiat Oncol Biol Phys 2002;54:1153–9. DOI: 10.1016/s0360-3016(02)03019-5.
30. Abusaris H., Hoogeman M., Nuyttens J.J. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer ResTreat 2012;11(6):591–7.
31. Tran P.T., Su Z., Hara W. et al. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int JRadiat Oncol Biol Phys 2007;69(2):504–11.
32. Barakat R.R., Goldman N.A., Patel D.A. et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75(1):99–102.
33. Morris M., Alvarez R.D., Kinney W.K. et al. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996;60(2):288–91.
34. Khoury-Collado F., Einstein M.H., Bochner B.H. et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol 2012;124(1):42–7.
35. Westin S.N., Rallapalli V., Fellman B. et al. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 2014;134 (3):546–51. DOI: 10.1016/j.ygyno.2014.06.034.
36. Ang C., Bryant A., Barton D.P. et al. Exenterative surgery for recurrent gynaecological malignancies. Cochrane Database Syst Rev 2014;4(2):CD010449.
37. Van Wijk F.H., van der Burg M.E., Burger C.W. et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009;19(3):314–20.
38. Zanfagnin V., Ferrero A., Biglia N. et al. The role of surgery in recurrent endometrial cancer. Expert Rev Anticancer Ther 2016;16(7):741–50.
39. Dowdy S.C., Mariani A., Cliby W.A. et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006;101(2):280–6.
40. Deodato F., Maccia G., Grimaldi L. et al. Stereotactic radiotherapy in recurrent gynecological cancer: A case series. Oncol Rep2009;22(2):415–9.
41. Sorolla M.A., Parisi E., Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers 2020;12(7): 1906. DOI: 10.3390/cancers12071906.
42. Potters L., Steinberg M., Rose C. et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guidelines for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004;60:1026–32.
43. Wulf J., Haedinger U., Oppitz U. et al. Stereotactic boost irradiation for targets in abdomen and pelvis. Radiother Oncol 2004;70:31–6. DOI: 10.1016/j.radonc.2003.10.013.
44. Lee L.J., Damato A.L., Viswanathan A.N. Clinical outcomes following 3D imageguided brachytherapy forvaginal recurrence of endometrial cancer. Gynecol Oncol 2013;131(3):586–92.
45. Piura B., Rabinovich A., Apel-Sarid L., Shaco-Levy R. Splenic metastasis from endometrial carcinoma: report of a case and review of literature. Arch Gynecol Obstet 2009;280(6):1001–6.
46. Tangjitgamol S., Levenback C.F., Beller U., Kavanagh J.J. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 2004;14(3):399–422.
47. Barlin J.N., Puri I., Bristow R.E. Cytoreductive surgery for advanced or recurrent endometrial cancer: a metaanalysis. Gynecol Oncol 2010;118(1):14–8.
48. Turan T., Tasci T., Karalok A. et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer 2015;25(9):1623–32. DOI: 10.1097/IGC.0000000000000543.
49. Papadia A., Bellati F., Ditto A. et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol 2015;22(13):4204–10.
50. Awtrey C.S., Cadungog M.G., Leitao M.M. et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 2006;102(3):480–8.
51. Salama J.K., Milano M.T. Radical irradiation of extracranial oligometastases. J Clin Oncol 2014;32(26):2902–12.
52. Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73. DOI: 10.1038/nature12113.
53. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019.
54. Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771.
55. Homesley H.D., Meltzer N.P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol 2008;13(1):62–5.
56. Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88(3):277–81.
57. Lissoni A., Zanetta G., Losa G. et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996;7(8):861–3. DOI: 10.1093/oxfordjournals.annonc.a010768.
58. Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004;92(1):180–2.
59. Fracasso P.M., Blessing J.A., Molpus K.L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;103(2):523–6.
60. Gupta D., Owers R.L., Kim M. et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009;113(3):327–30.
61. Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2002;87(3):247–51.
62. Muggia F.M., Blessing J.A., Sorosky J., Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20(9):2360–4.
63. Rose P.G., Blessing J.A., Lewandowski G.S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1996;63(1):101–4.
64. Pawinski A., Tumolo S., Hoesel G. et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999;86(2):179–83.
65. Miller D.S., Blessing J.A., Drake R.D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115(3):443–6.
66. Tait D.L., Blessing J.A., Hoffman J.S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011;121(1):118– 21. DOI: 10.1016/j.ygyno.2010.11.027.
67. Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73(5):1453–5.
68. Lentz S.S., Brady M.F., Major F.J. et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1996;14:357–61.
69. Levine D.A., Getz G., Gabriel S.B. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67–73.
70. Makker V., Green A.K., Wenham R.M. et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract 2017;4:19. DOI: 10.1186/s40661-0170056-7.
71. Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015;372:2509–20.
72. Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.
73. Mittica G., Ghisoni E., Giannone G. et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 2017;8(52):90532–44.
74. Hasegawa K., Tamura K., Katsumata N. et al. Efficacy and safety of nivolumab (Nivo) in patients (pts) with advancedor recurrent uterine cervical or corpus cancers. J Clin Oncol 2018;36(Suppl 15): 5594.
75. Konstantinopoulos P.A., Luo W., Liu J.F. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/ persistent endometrial cancer. J Clin Oncol 2019;37:2786–94. DOI: 10.1200/JCO.19.01021.
76. Antill Y., Kok P.S., Stockler M. et al. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). Ann Oncol 2019;30(Suppl 9): IX192.
77. Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the antiprogrammed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6:1766–72.
78. Clinical trials for 2018-001072-37. Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001072-37.
79. Antill Y.C., Kok P.-S., Robledo K.P. et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). J Clon Oncol 2019;37(15 Suppl):5501.
80. Arora S., Balasubramaniam S., Zhang W. et al. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res2020;26(19):5062–7. DOI:10.1158/1078-0432.CCR-19-3979.
81. Makker V., Colombo N., Herraez A.C. et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775.SGO Annual Meeting 2021.
Рецензия
Для цитирования:
Морхов К.Ю., Крейнина Ю.М., Покатаев И.А., Нечушкина В.М. Междисциплинарный подход к ведению пациенток при прогрессировании рака тела матки. Опухоли женской репродуктивной системы. 2022;18(1):87-96. https://doi.org/10.17650/1994-4098-2022-18-1-87-96
For citation:
Morkhov K.Yu., Kreinina Yu.M., Pokataev I.A., Nechushkina V.M. Interdisciplinary approach to the management of patients with uterine cancer progression. Tumors of female reproductive system. 2022;18(1):87-96. (In Russ.) https://doi.org/10.17650/1994-4098-2022-18-1-87-96
Просмотров: 72
Послать статью по эл. почте 
